1. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration

   • Catia Marzolini
   • Laurent A. Decosterd
   • Ferdy Lejeune

   ORIGINAL ARTICLE Pages: 433 - 440

2. Lack of correlation of MRP and γ-glutamylcysteine synthetase overexpression with doxorubicin resistance due to increased apoptosis in SV40 large T-antigen-transformed human mesothelial cells

   • Besim Ogretmen
   • Hamid Bahadori
   • Ahmad R. Safa

   ORIGINAL ARTICLE Pages: 441 - 446

3. Antihelicase action of CI-958, a new drug for prostate cancer

   • Lapman Lun
   • Pei-Ming Sun
   • Nicholas R. Bachur

   ORIGINAL ARTICLE Pages: 447 - 453

4. Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines

   • A. Pierré
   • S. Léonce
   • G. Atassi

   ORIGINAL ARTICLE Pages: 454 - 460

5. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer

   • Murray S. Webb
   • Patricia Logan
   • Marcel B. Bally

   ORIGINAL ARTICLE Pages: 461 - 470

6. Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration

   • Moustapha Hassan
   • Zuzana Hassan
   • Nils Kållberg

   ORIGINAL ARTICLE Pages: 471 - 478

7. Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors

   • Matthew L. Hanley
   • Gertrude B. Elion
   • Henry S. Friedman

   ORIGINAL ARTICLE Pages: 479 - 482

8. Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil

   • Punya Shrivastava
   • Masaki Hanibuchi
   • Saburo Sone

   ORIGINAL ARTICLE Pages: 483 - 490

9. Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma

   • Hideya Takeuchi
   • Gulshan Ara
   • Beverly Teicher

   ORIGINAL ARTICLE Pages: 491 - 496

10. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer

    • Colleen J. Gilbert
    • William P. Petros
    • William P. Peters

    ORIGINAL ARTICLE Pages: 497 - 503

11. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically

    • Primo N. Lara Jr.
    • David R. Gandara
    • Mike DeGregorio

    ORIGINAL ARTICLE Pages: 504 - 508

12. Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration

    • Nicolas B. Tsavaris
    • Christos Kosmas

    SHORT COMMUNICATIONS Pages: 509 - 511

13. Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels

    • Dick de Vos
    • Peter H. T. J. Slee
    • Derek Stevenson

    SHORT COMMUNICATION Pages: 512 - 514